Helicobacter pylori and oral –gut microbiome: clinical implications

AbstractMore than half of the world ’s population are colonized with H. pylori; however, the prevalence varies geographically with the highest incidence in Africa.H. pylori is probably a commensal organism that has been associated with the development of gastritis, ulcers, and gastric cancer.H. pylori alone is most probably not enough for the development of gastric carcinoma, but evidence for its association with the disease is high and has, therefore, been classified by the International Agency for Research on Cancer as a Class 1 carcinogen. Bacteroidetes and Fusobacteria positively coexisted duringH. pylori infection along the oral –gut axis. The eradication therapy required to treatH. pylori infection can also have detrimental consequences for the gut microbiota, leading to a decreased alpha diversity. Therefore, therapy regimens integrated with probiotics may abolish the negative effects of antibiotic therapy on the gut microbiota. These eradication therapies combined with probiotics have also higher rates of eradication, when compared to standard treatments, and are associated with reduced side effects, improving the patient ’s compliance. The eradication therapy not only affects gut microbiome but also affects the oral microbiome with robust predominance of harmful bacteria. However, there have been reports of a protective role ofH. pylori in Barrett ’s esophagus, esophageal adenocarcinoma, eosinophilic esophagitis, IBD, asthma, and even multiple sclerosis. Ther...
Source: Infection - Category: Infectious Diseases Source Type: research